Aggressive investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LPCN no adcom!!
$LPCN - no adcom !!!
$LPCN Adopts Stockholder Rights Plan
http://ir.lipocine.com/releasedetail.cfm?ReleaseID=942723
$LPCN Adopts Stockholder Rights Plan
http://ir.lipocine.com/releasedetail.cfm?ReleaseID=942723
$LPCN announces PDUFA Goal Date for LPCN 1021 NDA...
http://www.nasdaq.com/press-release/lipocine-announces-pdufa-goal-date-for-lpcn-1021-nda-20151112-01129
$LPCN announces PDUFA Goal Date for LPCN 1021 NDA...
http://www.nasdaq.com/press-release/lipocine-announces-pdufa-goal-date-for-lpcn-1021-nda-20151112-01129
$LPCN sky has no limit ....
Lipocine Announces PDUFA Goal Date for LPCN 1021 NDA
http://www.nasdaq.com/press-release/lipocine-announces-pdufa-goal-date-for-lpcn-1021-nda-20151112-01129#ixzz3rNoFVIGv
Nuvo Research's (NRIFF) CEO John London on Q3 2015 Results - Earnings Call Transcript
http://seekingalpha.com/article/3676436-nuvo-researchs-nriff-ceo-john-london-on-q3-2015-results-earnings-call-transcript?auth_param=i5mo:1b4712i:070446b61e411cc8557fd692f9b5e8a8
Nuvo Research's (NRIFF) CEO John London on Q3 2015 Results - Earnings Call Transcript
http://seekingalpha.com/article/3676436-nuvo-researchs-nriff-ceo-john-london-on-q3-2015-results-earnings-call-transcript?auth_param=i5mo:1b4712i:070446b61e411cc8557fd692f9b5e8a8
Multiple sclerosis is Lyme disease: Anatomy of a cover-up
https://nurse194666.wordpress.com/2015/10/04/multiple-sclerosis-is-lyme-disease-anatomy-of-a-cover-up/
RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
http://globenewswire.ca/news-release/2015/11/09/785064/10155663/en/RedHill-Biopharma-and-IntelGenx-Announce-First-European-Marketing-Approval-of-RIZAPORT-TM-RHB-103-for-Migraines.html#sthash.waxXktXs.dpuf
$IGXT (TSX: IGX) & RedHill Biopharma Announce First European Marketing Approval of RIZAPORT(TM) for Migraine
http://web.tmxmoney.com/article.php?newsid=80483045&qm_symbol=IGX
$IGXT (TSX: IGX) & RedHill Biopharma Announce First European Marketing Approval of RIZAPORT(TM) for Migraine
http://web.tmxmoney.com/article.php?newsid=80483045&qm_symbol=IGX
Dr Peter Gøtzsche Exposes Big Pharma as Organized Crime
http://healthimpactnews.com/2015/dr-peter-gotzsche-exposes-big-pharma-as-organized-crime/#sthash.xhCKTTby.dpuf
$NRIFF Announces Successful Pennsaid®2% Phase 3 Trial for Russia
http://web.tmxmoney.com/article.php?newsid=80393205&qm_symbol=NRI
$NRIFF Announces Successful Pennsaid®2% Phase 3 Trial for Russia
http://web.tmxmoney.com/article.php?newsid=80393205&qm_symbol=NRI
$VRX Valeant Pharmaceuticals Intl Inc. Has Lost $100 Billion in Value Since August. Is it Going to $0?
http://www.fool.ca/2015/11/03/valeant-pharmaceuticals-intl-inc-has-lost-100-billion-in-value-since-august-is-it-going-to-0/
$VRX Valeant Pharmaceuticals Intl Inc. Has Lost $100 Billion in Value Since August. Is it Going to $0?
http://www.fool.ca/2015/11/03/valeant-pharmaceuticals-intl-inc-has-lost-100-billion-in-value-since-august-is-it-going-to-0/
$IGXT Reports Record Third Quarter 2015 Financial Results
http://web.tmxmoney.com/article.php?newsid=80329892&qm_symbol=IGX
$LPCN - FDA Accepts for Filing Lipocine’s NDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021. PDUFA 8/29/16 (est)
http://www.smarteranalyst.com/2015/11/02/analysts-bullish-on-biotech-giants-keryx-biopharmaceuticals-inc-kerx-and-lipocine-inc-nasdaqlpcn/
$LPCN - FDA Accepts for Filing Lipocine’s NDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021. PDUFA 8/29/16 (est)
http://www.smarteranalyst.com/2015/11/02/analysts-bullish-on-biotech-giants-keryx-biopharmaceuticals-inc-kerx-and-lipocine-inc-nasdaqlpcn/
Analysts Bullish on Biotech Giant $LPCN ...
http://www.smarteranalyst.com/2015/11/02/analysts-bullish-on-biotech-giants-keryx-biopharmaceuticals-inc-kerx-and-lipocine-inc-nasdaqlpcn/
Analysts Bullish on Biotech Giant $LPCN ...
http://www.smarteranalyst.com/2015/11/02/analysts-bullish-on-biotech-giants-keryx-biopharmaceuticals-inc-kerx-and-lipocine-inc-nasdaqlpcn/
$LPCN a reversal might be near
Supreme Pharmaceuticals Building the "Wal-Mart" of Medical Marijuana
http://www.stockhouse.com/companies/enhanced-profiles/supreme-pharmaceuticals-inc/overview
Supreme Pharmaceuticals Building the "Wal-Mart" of Medical Marijuana
http://www.stockhouse.com/companies/enhanced-profiles/supreme-pharmaceuticals-inc/overview
$LPCN - FDA Accepts for Filing Lipocine’s New Drug Application for Its Oral Testosterone Replacement Product Candidate, LPCN 1021
http://www.nasdaq.com/press-release/fda-accepts-for-filing-lipocines-new-drug-application-for-its-oral-testosterone-replacement-produc-20151029-01448#ixzz3q3rgYf2s
$LPCN - FDA Accepts for Filing Lipocine’s New Drug Application for Its Oral Testosterone Replacement Product Candidate, LPCN 1021
http://www.nasdaq.com/press-release/fda-accepts-for-filing-lipocines-new-drug-application-for-its-oral-testosterone-replacement-produc-20151029-01448#ixzz3q3rgYf2s
SPRWF - great Canadian POT play
SPRWF - great Canadian POT play!!!
Controversial biotech CEO Martin Shkreli just lost money on his 'bad idea' Valeant bet
https://finance.yahoo.com/news/controversial-biotech-ceo-martin-shkreli-182531374.html
Marijuana legalization could draw U.S investment bonanza to Canada
http://www.cbc.ca/news/business/marijuana-legalization-could-draw-u-s-investment-bonanza-to-canada-1.3288480
Supreme Pharmaceuticals Inc.
OTCBB : SPRWF
CNSX : SL
Goodbye Middle Class: 51 Percent Of All American Workers Make Less Than 30,000 Dollars A Year
http://endoftheamericandream.com/archives/goodbye-middle-class-51-percent-of-all-american-workers-make-less-than-30000-dollars-a-year
Thanks. Backfired
Not in the money....lol. Unless confirm QE in the place, market will behave like this.
$LPCN FDA Approval on Track for 2016…
https://finance.yahoo.com/news/lpcn-files-nda-lpcn-1021-200000373.html
$LPCN FDA Approval on Track for 2016…
https://finance.yahoo.com/news/lpcn-files-nda-lpcn-1021-200000373.html
$LPCN Updated corporate presentation
http://files.shareholder.com/downloads/AMDA-2BVSIV/865335907x0x854540/02A0C183-90F8-4111-9DFD-53EF25A00674/LPCN_Presentation_October_FINAL.pdf
Highlights
First oral testosterone replacement option
– Targeting ~ $2.0 Billion TRT market
– NDA submitted August 2015
– Differentiated from existing products
Orphan designated oral alternative for the prevention of preterm birth
– Avoids painful injections of the only FDA approved intra-muscular drug
– Multi-dose PK study expected to start 4Q 2015
Strong Balance Sheet
– Over $53M in Cash as of June 30th – Sufficient to last past LPCN 1021 anticipated
PDUFA date
– No Debt